Market corrections are always scary when they happen but, fortunately, they don't come around too often. The previous meltdown for biopharmaceutical equities was back in February 2016. This time around, the BioWorld Biopharmaceutical index experienced a dramatic drop of 10 percent in October, with the BioWorld Drug Developers index suffering an almost 19 percent swoon. A late market rally did help stop the bleeding but by then the damage had been done, leaving investors to lick their wounds and the sector to face an uphill battle to recover its losses before the close of the year.